New Outpatient Treatment Options for Covid-19

Devang Patel, MD and Neda Frayha, MD

on Spotify

The summary below is from an episode of ERcast: Clinical Perspectives

Early outpatient COVID-19 treatment works best when started soon after symptom onset in high-risk patients. Oral antivirals, remdesivir, monoclonal antibodies, and pre-exposure prophylaxis each have different access barriers, interaction risks, and real-world logistics that matter at the bedside.

Outpatient Covid Therapeutic Options

Early treatment window: Benefit is front-loaded in nonhospitalized COVID-19, so the key bedside move is recognizing high-risk patients quickly and starting authorized therapy before the window closes.
Paxlovid first-line role: Nirmatrelvir-ritonavir became the headline oral option because it sharply lowers progression risk, but ritonavir drug interactions are the practical rate-limiter clinicians need to screen for.
Molnupiravir backup option: Molnupiravir is the oral fallback when better options are unavailable or contraindicated, with lower efficacy and important pregnancy-related cautions that shape who should receive it.
Three-day remdesivir course: Outpatient remdesivir offers a strong non-oral alternative with a 3-day IV regimen that can prevent hospitalization, and the referral logistics are worth hearing in the episode.
Monoclonal antibody churn: Neutralizing monoclonal antibodies were useful only when local variant susceptibility matched the product, making formulary choice a moving target rather than a set-and-forget order.
Therapeutics locator tools: Federal and state treatment locators became essential because the best agent on paper was often irrelevant if local supply, infusion capacity, or dispensing pathways could not support it.

Pre-Exposure Prophylaxis Access

Evusheld prevention role: Tixagevimab-cilgavimab offered pre-exposure prophylaxis for selected patients unlikely to mount adequate vaccine protection, especially the moderately to severely immunocompromised.
Not post-exposure treatment: Pre-exposure prophylaxis is a prevention strategy, not a substitute for vaccination or a treatment for active infection, and that distinction prevents common ordering errors.
Patient selection priority: When supply is constrained, prioritization hinges on immunocompromise and risk for severe disease rather than a first-come, first-served approach. We get into the triage logic in the chapter.
Operational access barriers: Real-world use depends on EUA criteria, product availability, and local administration pathways, so knowing where the drug exists is often as important as knowing it exists.

Subscribe to ERcast: Clinical Perspectives to listen to the episode.

Resources:

Faculty

Neda Frayha, MD
Neda Frayha, MD, is Audio Editor-in-Chief at Hippo Education and host of the Primary Care Reviews and Perspectives and Hippo Education Presents: The Monthly Rounds podcasts. She is a primary care internist who completed her residency and chief residency at the University of Maryland.
Devang Patel, MD